Trials / Completed
CompletedNCT02663921
Visible Light Study
Determination of the Minimal Dose of Visible Light Required to Achieve Immediate Pigment Darkening, Persistent Pigment Darkening, and Delayed Tanning for Fitzpatrick Skin Types IV-VI Utilizing Two Visible Light Sources.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn more about the potential effects of visible light on the skin. More specifically, this study will examine whether an incandescent lamp (light bulb) or LED light bulb can cause skin to become darker. Investigators will determine the minimum threshold dose required to achieve immediate pigmentation darkening (IPD), persistent pigmentation darkening (PPD), and delayed tanning (DT) for Fitzpatrick skin types IV - VI utilizing two visible light sources.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Part A: Baseline-Week 2 | The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points: 1. Immediately after the light exposure; 2. 30 minutes after light exposure; and 3. 1 hour after light exposure. |
| OTHER | Part B: Week 4-Week 12 | The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography 1. Visual Clinical Assessment 2. Spectroscopy 3. Colorimetry |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2019-04-17
- Completion
- 2019-04-17
- First posted
- 2016-01-26
- Last updated
- 2019-06-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02663921. Inclusion in this directory is not an endorsement.